logo

EXELIXIS I(NSDQ:EXEL)
Exelixis Inc. is a leader in the fields of model system genetics andcomparative genomics. These fields involve the systematic study of simpleorganisms, such as fruit flies, nematodes, mice, zebrafish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode.
# Employees: 676
Address: 170 Harbor Way P.O. Box 511,South San Francisco,CA,USA
Phone: 650 837-7000
Fax: 650 837-8300
Website: www.exelixis.com
Email: cbutler@exelixis.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Stelios Papadopoulos Ph.D. (Chmn.)
George A. Scangos Ph.D. (Presi.; C.E.O.)
Frank Karbe (C.F.O.)
Vincent Marchesi MD (Ph)
Dir. (Charles Cohen Ph.D.,Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 3/10/2010
Mean EPS (Next Qtr): ($0.25)
Mean EPS (Year): ($1.23)
Mean Estimate(Long Term): ($0.01)
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 9
Shares Performance
Period EXEL Compare to S&P
YTD 33.67 % 10.62 %
4 Weeks 14.90 % 13.66 %
12 Weeks 17.51 % 10.79 %
Shares Information
Analyst Coverage: Y
Avg Volume: 1343619
Shares Outstanding: 107M
Market Cap: $0.72B
52 Week High: $7.69
52 Week Low: $2.40
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 EXEL split by factor of 2.000
Earnings Performance
EPS Growth in Last Quarter: 33.33 %
EPS Growth in Last Year: 43.59 %
Sales Growth in Last Quarter: 100.63 %
Sales Growth in Last Quarter: 83.67 %
Financials
Qtr Book Value: ($0.01)
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 5.250
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia